Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | PGR | P06401 | 2/20 | 0.66 |
| ▸ | AR | P10275 | 2/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | SHBG | P04278 | 1/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | SNCA | P37840 | 1/20 | 0.66 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.66 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369302 | 1.00 | ESR1 (0.66) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL6364269 | 0.90 | USP2 (0.63) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL3370188 | 0.90 | USP2 (0.63) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL2517551 | 0.89 | ABCC4 (0.76) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL5521870 | 0.89 | ABCC4 (0.76) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL6440061 | 0.88 | KDM4E (0.76) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL6369320 | 0.88 | STS (0.76) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL345571 | 0.88 | STS (0.76) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL4382857 | 0.87 | ABCC4 (0.80) | ESR1LMNAESR2CYP2C9PGR | |
| SCHEMBL6364570 | 0.87 | ABCC4 (0.80) | ESR1LMNAESR2CYP2C9PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0775156-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRA-1,3,5(10)-TRIENE DERIVATIVES | JENAPHARM GMBH (DE) | 2003-09-03 | — | — | EP | claimed |
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | STERIX LIMITED (GB) | 2002-05-23 | — | — | US | claimed |
| US-6080735-A | SUITABLE FOR HORMONAL CONTRACEPTION AND CLIMACTERIC HORMONE REPLACEMENT THERAPY (HRT) AS WELL AS FOR TREATMENT OF GYNECOLOGICAL AND ANDROLOGICAL DISEASES | JENAPHARM GMBH & CO. KG (DE) | 2000-06-27 | — | — | US | claimed |
| EP-1284273-B1 | Estra-1,3,5(10)-trien-3-sulfamates a process for their production and pharmaceutical compositions containing them | STERIX LTD (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-6841548-B2 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | SCHERING AG (DE) | 2005-01-11 | — | — | US | disclosed |
| EP-0775156-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRA-1,3,5(10)-TRIENE DERIVATIVES | JENAPHARM GMBH (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-6569844-B1 | Hormonal contraception and hormon replacement therapy with low hepatic estrogenity | JENAPHARM GMBH & CO., KG (DE) | 2003-05-27 | — | — | US | disclosed |
| EP-1284273-A2 | Estra-1,3,5(10)-trien-3-sulfamates a process for their production and pharmaceutical compositions containing them | JENAPHARM GmbH (DE) | 2003-02-19 | — | — | EP | disclosed |
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | STERIX LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| US-6080735-A | SUITABLE FOR HORMONAL CONTRACEPTION AND CLIMACTERIC HORMONE REPLACEMENT THERAPY (HRT) AS WELL AS FOR TREATMENT OF GYNECOLOGICAL AND ANDROLOGICAL DISEASES | JENAPHARM GMBH & CO. KG (DE) | 2000-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | ESRRA, ESR2, CYP19A1 | ESR1 4/4885LMNA 3218/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.